國藥科技股份(08156.HK)中期收入激增逾6倍至8738萬港元
格隆匯2月13日丨國藥科技股份(08156.HK)公佈,截至2019年12月31日止6個月,實現收入約8738萬港元,同比增606.10%;股權持有人應占虧損1723.5萬港元,同比收窄8.84%;每股基本虧損0.42港仙。不派息。
於回顧期間,集團的業務在已開展的健康、公共安全、政務、租賃、彩票等業務基礎上,對"互聯網+"與傳統業務結合的兩大領域—"互聯網+彩票"與"互聯網+健康"進行重點推動與拓展,與各具優勢的企業達成合作意向,擴張"互聯網+"商業版圖。
此等商業行動有效豐富與完善集團的商業佈局網絡,且與商業合作伙伴的戰略聯繫及合作得到進一步鞏固和加強。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.